AACE Annual Meeting 2025 Conference Recap

Published: May 19, 2025

The American Association of Clinical Endocrinology just wrapped up its 2025 annual conference. From May 15 through May 17, 2025, thousands of experts from the endocrinology field gathered to discuss, network, and learn at the event’s sessions and discussions.

With more than 75 sessions and 550 abstracts presented at AACE 2025, there was plenty of exciting data for attendees to digest. When we previewed the event, back in April, we highlighted some of the sessions related to diabetes. Here’s a look at each of the presented conclusions.

Minimizing Severe Hypo - and Hyperglycemia in the Hospital Setting

Description: Hospitalized patients with diabetes are at increased risk of adverse outcomes when glycemic control is suboptimal. This session will address current challenges, including the absence of standardized glucose data benchmarks and limited data extraction capabilities.
Conclusion: Hospitals need to partner with nurses, endocrine hospitals, diabetes educators, pharmacists, internal IT teams to coordinate adequate care for balancing hypo- and hyperglycemia. Making hospitals safer across the country starts with standardizing the quality of diabetes care.

Managing Diabetes in Adolescents and Young Adults

Description: A review of case-based strategies for managing glycemia in adolescent and young adult populations, particularly in camp and transitional care settings, with a focus on navigating diabetes technology, risk mitigation for hypoglycemia, and other patient-specific challenges.
Conclusions: Discussing safe practices in newfound freedoms of young adulthood are key to the success and safety of young patients with diabetes. There are GLP-1 and SGLP-2 medications that are approved for adolescents with type 2 diabetes. Type 1 diabetes should be considered in adolescents who are obese or overweight.

Should CGM be Used for People Without Diabetes?

Description: A presentation of the latest clinical perspectives and research on CGM utility in prediabetes and normoglycemic populations, with implications for preventative endocrinology and personalized metabolic care.
Conclusions: CGM use is useful and feasible for people living with prediabetes. Some short-term benefits were observed. A long-term trial is needed to assess the benefits of CGM within the same population. CGM spikes may be normal, but more studies need to be conducted. Current CGM metrics are for people with diabetes, not for people without diabetes.

Is Type 2 Diabetes Remission Sustainable with Diet or Lifestyle Changes?

Description: Longitudinal data on dietary and lifestyle interventions for T2D remission were examined, with an emphasis on characteristics associated with sustained remission, clinician biases about dietary efficacy, the potential for precision nutrition approaches, and the evolving role of artificial intelligence in personalized metabolic therapy.
Conclusions: Barriers for healthcare providers offering lifestyle as a first-line treatment option for type 2 diabetes are also barriers for patients. Lifestyle-driving remission worked for 46% of patients within the first year. 36% remained in remission a year later.

South Asia’s Diabetes Hotspot - Local Disease Burden and its Regional Implications

Description: Explored the regional burden of diabetes in South Asia and its implications for clinical practice.
Conclusion: Diabetes prevalence is rising in Asia at an alarming rate due to many factors. Holistic, team-based care is needed to educate the culturally varied population of Asia about their risk factors and emphasis on lifestyle changes is key.

For a full look at AACE 2025’s schedule and all the presentations, visit the event’s website.